Separate Safety Center Could Impair Oversight “Continuity” - Von Eschenbach

Creating "separate and independent" centers for drug approval and post-approval safety surveillance "would not improve the FDA's ability to fulfill its mission to protect the public health," FDA Acting Commissioner Andrew von Eschenbach asserted